Literature DB >> 7695294

Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro.

M L Barclay1, E J Begg, S T Chambers, D R Boswell.   

Abstract

First doses of aminoglycoside and beta-lactam antibiotics, when used in combination, are usually given simultaneously; however, nonsimultaneous administration may be more efficacious. We used a dynamic in vitro model, which simulates in vivo serum kinetics, to assess the effect of spacing the first doses of gentamicin and ceftazidime used against Pseudomonas aeruginosa ATCC 27853 and two clinical isolates of P. aeruginosa, PA1 and PA2. The following dose regimens against P. aeruginosa ATCC 27853 were compared: (i) gentamicin given alone, (ii) ceftazidime given alone, (iii) gentamicin and ceftazidime given simultaneously, (iv) gentamicin followed by ceftazidime at 15 or 50 min or at 2, 4, or 8 h, and (v) ceftazidime which was followed by gentamicin at 4 h. The effects of regimen iii and the 4-h interval in regimen iv against PA1 and PA2 were also compared. Initial peak concentrations used were 8 mg/liter for gentamicin and 80 mg/liter for ceftazidime, with drug half-lives of 2.5 and 1.8 h, respectively. Compared with simultaneous administration, nonsimultaneous administration (regimens iv and v) produced greater overall bacterial killing and was associated with a delay in bacterial regrowth (p < 0.005) of up to 6.6 to 8.3 h, regardless of the order in which the drugs were given. The optimal interval between gentamicin and ceftazidime doses, which maximized initial bactericidal effect and the time before regrowth, appeared to be 2 to 4 h.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695294      PMCID: PMC162498          DOI: 10.1128/AAC.39.1.132

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Effect of ceftazidime, cefotaxime, and cefoperazone on serum tobramycin concentrations.

Authors:  A T Pennell; D R Allington; M H Chandler
Journal:  Am J Hosp Pharm       Date:  1991-03

2.  Kill kinetics of bacteria under fluctuating concentrations of various antibiotics. II. Description of experiments.

Authors:  P König; J P Guggenbichler; E Semenitz; W Foisner
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

3.  The postantibiotic effect.

Authors:  W A Craig; B Vogelman
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

4.  Spaced administration of antibiotic combinations to eliminate pseudomonas from sputum in cystic fibrosis.

Authors:  J P Guggenbichler; F Allerberger; M P Dierich; R Schmitzberger; E Semenitz
Journal:  Lancet       Date:  1988-09-24       Impact factor: 79.321

5.  Determination of cephalosporins in biological material by reversed-phase liquid column chromatography.

Authors:  A M Brisson; J B Fourtillan
Journal:  J Chromatogr       Date:  1981-05-08

6.  In vitro inactivation of aminoglycosides by cephalosporin antibiotics.

Authors:  D N Wright; D A Marble; B Saxon; C C Johnson; J A Bosso; J M Matsen
Journal:  Arch Pathol Lab Med       Date:  1988-05       Impact factor: 5.534

7.  In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G J Malanoski; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

8.  Synergy of levofloxacin (L-ofloxacin) and oxacillin against quinolone-resistant Staphylococcus aureus, measured by the time-kill method.

Authors:  J A Patel; C T Pachucki; J R Lentino
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

9.  Antimicrobial effects of lomefloxacin in vitro.

Authors:  S T Chambers; B A Peddie; R A Robson; E J Begg; D R Boswell
Journal:  J Antimicrob Chemother       Date:  1991-04       Impact factor: 5.790

10.  Bactericidal activity of the fluoroquinolone WIN 57273 against high-level gentamicin-resistant Enterococcus faecalis.

Authors:  G A Noskin; P Mehl; J R Warren
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more
  5 in total

1.  Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.

Authors:  J G den Hollander; J W Mouton; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.

Authors:  J G den Hollander; A M Horrevorts; M L van Goor; H A Verbrugh; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

3.  Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.

Authors:  P M Beringer; A A Vinks; R W Jelliffe; B J Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

4.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

Review 5.  Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

Authors:  Alexandre Boyer; Didier Gruson; Stéphane Bouchet; Benjamin Clouzeau; Bui Hoang-Nam; Frédéric Vargas; Hilbert Gilles; Mathieu Molimard; Anne-Marie Rogues; Nicholas Moore
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.